SCHEMBL14896296

SCHEMBL14896296

Nc1cc(-c2cccs2)no1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.50
NPC1 O15118 4/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
KDM4E B2RXH2 7/20 0.47
ALDH1A1 P00352 5/20 0.47
MAPT P10636 4/20 0.47
BLM P54132 1/20 0.47
MEN1 O00255 2/20 0.47
HPGD P15428 2/20 0.47
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TDO2 P48775 1/20 0.46
ADORA2A P29274 2/20 0.43
ADORA1 P30542 2/20 0.43
PIM1 P11309 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5904743 0.78 KDM4E (0.47) HSD17B10NPC1CYP1A2CYP3A4CYP2D6
SCHEMBL11961408 0.78 ALDH1A1 (0.50) HSD17B10NPC1CYP1A2CYP3A4CYP2D6
SCHEMBL7020024 0.78 KDM4E (0.47) HSD17B10NPC1CYP1A2CYP3A4CYP2D6
SCHEMBL27847623 0.76 KDM4E (0.46) HSD17B10NPC1CYP1A2CYP3A4CYP2D6
SCHEMBL28677516 0.75 RAB9A (0.65) NPC1CYP1A2CYP2C9CYP2C19KDM4E
SCHEMBL17874008 0.75 RET (0.46) HSD17B10NPC1CYP1A2CYP3A4CYP2D6
SCHEMBL15029059 0.74 CA12 (0.49) HSD17B10NPC1CYP1A2CYP3A4CYP2D6
SCHEMBL2761387 0.74 SMN1; SMN2 (0.50) HSD17B10NPC1KDM4EALDH1A1MAPT
SCHEMBL17874000 0.73 KDM4E (0.47) HSD17B10NPC1KDM4EALDH1A1MAPT
SCHEMBL2766579 0.71 SMN1; SMN2 (0.44) HSD17B10NPC1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114920616-B Synthesis process of amidine compound 南京师范大学 2024-04-05 CN disclosed
CN-114920616-A Synthetic process of amidine compound 南京师范大学 2022-08-19 CN disclosed
US-9242995-B2 Isoxazolopyridine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-9242995-B2 Isoxazolopyridine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-9242995-B2 Isoxazolopyridine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2016-01-26 US disclosed
US-20150038502-A1 ISOXAZOLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2015-02-05 US disclosed
US-20150038502-A1 ISOXAZOLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2015-02-05 US disclosed
US-20150038502-A1 ISOXAZOLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2015-02-05 US disclosed
EP-2771346-A1 ISOXAZOLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2014-09-03 EP disclosed
WO-2013062858-A1 ISOXAZOLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2013-05-02 WO disclosed
WO-2013062858-A1 ISOXAZOLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038502-A1 ISOXAZOLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY5R HSD17B10 2543/4885NPC1 1343/4885CYP1A2 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.